Walleye Capital
IBIO icon

Walleye Capital’s iBio IBIO Stock Holding History

Walleye Capital’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$472K Sell
400,043
-100,332
-20% -$138K ﹤0.01% 4149
2026
Q2 		$876K Buy
500,375
+111,821
+29% +$200K ﹤0.01% 2237
2026
Q1 		$738K Buy
388,554
+190,179
+96% +$441K ﹤0.01% 2351
2025
Q4 		$383K Buy
+198,375
New +$271K ﹤0.01% 3124

Other funds holding IBIO

Silverarc Capital Management
Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Noesis Capital Mangement
Noesis Capital Mangement Boca Raton, Florida $843M AUM 33.46% 1-Year Est. Return

Walleye Capital's IBIO Position: Q3 2026 in Review

Walleye Capital reduced its iBio (IBIO) stake by 20% in Q3 2026, selling an estimated $138K and leaving 400,043 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #4149.

Walleye Capital first reported a position in IBIO in Q4 2025 and has held it in 4 quarters since. The position peaked at $876K in Q2 2026. 35 funds tracked by Wall St. Rank hold IBIO as of Q3 2026.

  • Walleye Capital held 400,043 shares of iBio worth $472K as of Q3 2026.
  • Walleye Capital sold 100,332 iBio shares in Q3 2026, an estimated $138K.
  • iBio made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4149 holding.
  • Walleye Capital first reported a position in iBio in Q4 2025 and has held it in 4 quarters since.
  • Walleye Capital's iBio position peaked at $876K in Q2 2026.
  • 35 funds tracked by Wall St. Rank held iBio as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.